We assessed the effect of S1R agonist FLU through in vivo and in vitro models, particularly focusing on the critical pathological pathways of DKD to determine its potential as an adjunct therapy for preserving kidney function. This evidence concerns the gene TMBIM4 and diabetic kidney disease.